+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Human Insulin Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon

    Report

  • 85 Pages
  • October 2022
  • Region: North America
  • Mordor Intelligence
  • ID: 4591712
The North America Human Insulin Drug Market is expected to register a CAGR greater than 4% by the forecast period (2022-2027).

In North America diabetes incidence for type 2 diabetes as well as other diabetes, forms were numerically higher in individuals with Covid-19. Insulin resistance and impaired insulin secretion have been described in individuals without diabetes history who recovered from SARS-CoV-2 infections. It has been suggested that diagnosis and treatment of post-Covid syndrome require integrated rather than disease-specific approaches.

North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market Trends

Lantus Holds The Highest Market Share in 2021

Lantus was approved by the US Food and Drug Administration (FDA) in April 2000. Lantus is a man-made form of hormone (insulin) that is produced in the body. Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Insulin glargine is a long-acting insulin that starts to work several hours after injection and keeps working evenly for 24 hours. Lantus is for use in adults with type 1 or types 2 diabetes, and in children at least 6 years old with type -1 Diabetes. For type 1 diabetes, Lantus is used together with short-acting insulin given before meals. Lantus and Januvia, two treatments for diabetes are some of the highest-selling drugs of all time and represent some of the greatest breakthroughs in diabetes control.

The United States was the largest market for Lantus in 2021, accounting for more than 58% of the market revenues. However, the biosimilars for Lantus may not present it with competitive challenges currently. The loss of exclusivity for Lantus may not result in the near-term disruption of the market for it. However, there will be additional pricing pressure and some loss of market share that would continue and may increase over time.



United States Holds Highest Market Share in 2021

Among the North American countries, the United States dominates around 94% of the total North America Human Insulin Drugs Market. This is mainly due to the high diabetes prevalence in the country. The United States records the highest healthcare expenditure globally, and it also has a higher adoption of advanced therapeutics. The United States accounts for the highest sales of long-acting insulin, Lantus, across the North America Region. Most diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the United States market.

The United States accounts for the highest sales of Humalog across the world, with over 56% of the market share. The majority of the diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50 for the treatment of diabetes.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.



Competitive Landscape

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. While in the remaining countries, the manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Insulin (Value and Volume 2016 - 2027)
5.1.1.1 Basal or Long-acting Insulin
5.1.1.1.1 Lantus (Insulin Glargine)
5.1.1.1.2 Levemir (Insulin Detemir)
5.1.1.1.3 Toujeo (Insulin Glargine)
5.1.1.1.4 Tresiba (Insulin Degludec)
5.1.1.1.5 Basaglar (Insulin Glargine)
5.1.1.2 Bolus or Fast-acting Insulin
5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.1.2.2 Humalog (Insulin Lispro)
5.1.1.2.3 Apidra (Insulin Glulisine)
5.1.1.2.4 FIASP (Insulin aspart)
5.1.1.2.5 Admelog (Insulin lispro)
5.1.1.3 Traditional Human Insulin
5.1.1.3.1 Novolin/Actrapid/Insulatard
5.1.1.3.2 Humulin
5.1.1.3.3 Insuman
5.1.1.4 Combination Insulin
5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)
5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
5.1.1.5 Biosimilar Insulin
5.1.1.5.1 Insulin Glargine Biosimilars
5.1.1.5.2 Human Insulin Biosimilars
5.2 Geography
5.2.1 United States (Value and Volume 2016 - 2027)
5.2.1.1 Basal or Long-acting Insulin
5.2.1.2 Bolus or Fast-acting Insulin
5.2.1.3 Traditional Human Insulin
5.2.1.4 Combination Insulin
5.2.1.5 Biosimilar Insulin
5.2.2 Canada (Value and Volume 2016 - 2027)
5.2.2.1 Basal or Long-acting Insulin
5.2.2.2 Bolus or Fast-acting Insulin
5.2.2.3 Traditional Human Insulin
5.2.2.4 Combination Insulin
5.2.2.5 Biosimilar Insulin
5.2.3 Rest of North America (Value and Volume 2016 - 2027)
5.2.3.1 Basal or Long-acting Insulin
5.2.3.2 Bolus or Fast-acting Insulin
5.2.3.3 Traditional Human Insulin
5.2.3.4 Combination Insulin
5.2.3.5 Biosimilar Insulin
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2016 - 2027)
6.2 Type 2 Diabetes Population (2016 - 2027)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.1.1 Overview
7.1.1.2 Products and Strategies
7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.1.4 Ratio Analysis (5 Years)
7.1.1.5 Strength and Stability Analysis (5 Years)
7.1.1.6 Recent Developments
7.1.2 Sanofi S.A.
7.1.2.1 Overview
7.1.2.2 Products and Strategies
7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.2.4 Ratio Analysis (5 Years)
7.1.2.5 Strength and Stability Analysis (5 Years)
7.1.2.6 Recent Developments
7.1.3 Eli Lilly and Company
7.1.3.1 Overview
7.1.3.2 Products and Strategies
7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.3.4 Ratio Analysis (5 Years)
7.1.3.5 Strength and Stability Analysis (5 Years)
7.1.3.6 Recent Developments
7.1.4 Biocon Limited
7.1.4.1 Overview
7.1.4.2 Products and Strategies
7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.4.4 Ratio Analysis (5 Years)
7.1.4.5 Strength and Stability Analysis (5 Years)
7.1.4.6 Recent Developments
7.1.5 Pfizer Inc.
7.1.5.1 Overview
7.1.5.2 Products and Strategies
7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.5.4 Ratio Analysis (5 Years)
7.1.5.5 Strength and Stability Analysis (5 Years)
7.1.5.6 Recent Developments
7.1.6 Wockhardt
7.1.6.1 Overview
7.1.6.2 Products and Strategies
7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.6.4 Ratio Analysis (5 Years)
7.1.6.5 Strength and Stability Analysis (5 Years)
7.1.6.6 Recent Developments
7.1.7 Julphar
7.1.7.1 Overview
7.1.7.2 Products and Strategies
7.1.7.3 Recent Developments
7.1.8 Exir
7.1.8.1 Overview
7.1.8.2 Products and Strategies
7.1.8.3 Recent Developments
7.1.9 Sedico
7.1.9.1 Overview
7.1.9.2 Products and Strategies
7.1.9.3 Recent Developments
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi S.A.
7.2.3 Eli Lilly and Company
7.2.4 Other Companies
8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novo Nordisk A/S
  • Sanofi S.A.
  • Eli Lilly and Company
  • Biocon Limited
  • Pfizer Inc.
  • Wockhardt
  • Julphar
  • Exir
  • Sedico

Methodology

Loading
LOADING...